
Altera's Integrated Operating Theater System Successfully Launches at Latrobe Regional Health
BUSINESS WIRE)-- Altera Digital Health is proud to announce the successful activation of its integrated operating theater system at Latrobe Regional Health (LRH), one of the hospital members of Gippsland Health Alliance (GHA). GHA has been leveraging Sunrise™ as its enterprise-wide electronic health record (EHR) platform, utilizing Microsoft Azure to enhance interoperability, security and scalability across its network.
As part of its ongoing digital transformation, GHA has now implemented an anesthesia information management system (AIMS) platform called Provation ® iPro to integrate with Sunrise at LRH. This milestone deployment of Sunrise Surgical Care and Provation iPro AIMS streamlines theater management and clinical documentation, enabling efficient surgical scheduling and ensuring a seamless patient experience with a single clinical record from pre-admission to discharge.
A Streamlined Approach to Theater Management
The successful deployment of Sunrise Surgical Care at LRH marks the first implementation of this advanced surgical management solution in Australia. Fully integrated with Sunrise EHR, Sunrise Surgical Care enhances efficiency by enabling real-time tracking of theater utilization, optimized scheduling and improved resource allocation. This implementation reinforces LRH's commitment to delivering high-quality, patient-centric care by reducing administrative burdens and ensuring timely access to critical surgical data.
Sunrise Surgical Care also plays a key role in supporting a continuous, single patient record from perioperative care to discharge. By providing clinicians with a comprehensive view of each patient's surgical journey, the system strengthens communication between healthcare providers and enhances patient safety and outcomes.
Additionally, the deployment of the Provation iPro AIMS platform spans 12 operating theaters and 18 Post-Anesthetic Care Unit (PACU) beds at LRH. Designed by practicing anesthetists, Provation iPro streamlines electronic anesthesia documentation throughout the entire perioperative encounter, standardizes the collection of quality measures and even streamlines billing processes.
Provation iPro's integration with Sunrise Surgical Care creates a seamless user experience, eliminating manual, redundant data entry. With this technology, Pre-Admissions clinics have transitioned from paper to digital records, populating data from Pre-Admission assessments into the day-of-surgery record, streamlining the theater admission process.
Provation iPro's autovitals feature wirelessly streams patient vitals from anesthesia monitor machines directly into the clinical record. With this, alongside a number of other thoughtful features, including picture-documentation, pre-filled procedure templates and hard-stops, providers can refocus their attention on the patient while simultaneously producing a more complete, compliant, legible anesthesia record.
Unlike traditional paper systems, these digital records can now be accessed and viewed by multiple clinicians across multiple locations simultaneously, enhancing collaboration and ensuring all relevant information is available in real time.
To keep families informed, LRH has introduced a "Patient Procedure Tracker" board in waiting areas, providing real-time updates on which stage of the theater journey their loved one is in — whether they are in pre-op, surgery, or recovery. This helps reduce uncertainty and minimizes the need for calls to reception.
Advancing Digital Transformation in Healthcare
Latrobe Regional Health's adoption of this operating theater system marks a significant step in its digital transformation journey. By leveraging advanced clinical technology, LRH is setting a new standard for theater efficiency, patient management and operational effectiveness.
Jon Millar, Chief Operating Officer at LRH, added, "This deployment at LRH showcases our strong partnership with Altera. Leveraging this technology enhances patient experiences and ensures seamless care delivery across our facility. Performing more than 10,000 surgical procedures per year, LRH is utilizing this system to enhance efficiency, streamline workflows and improve patient care. The ability to maintain a single clinical record from pre-admission to discharge is a game-changer for both staff and patients."
Todd Haebich, EVP, APAC at Altera Digital Health, shared, "The successful activation of Sunrise Surgical Care and Provation iPro at Latrobe Regional Health is a significant milestone for Altera, Provation and Gippsland Health Alliance. By equipping healthcare facilities with advanced tools, we empower clinicians to enhance patient care while optimizing workflows. This deployment highlights our ongoing commitment to supporting digital innovation in healthcare."
Enhancing Patient Care Through Integration
This launch aligns with the recent $223.5 million expansion of Latrobe Regional Health in Traralgon, which has significantly increased the hospital's capacity and services. With this multi-stage project now complete, local families can access world-class care closer to home, further strengthening the impact of Sunrise Surgical Care and Provation iPro in delivering high-quality patient outcomes.
For clinicians, these systems reduce the need for manual data entry, produce legible, complete anesthesia records, minimize duplication of records and enhance visibility into real-time theater utilization. These efficiencies contribute to better resource planning, fewer delays and improved surgical outcomes.
Commitment to Innovation and Excellence
This deployment reinforces Altera's commitment to supporting healthcare innovation across the region, ensuring that hospitals and clinicians have the tools they need to deliver exceptional care now and into the future.
About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera's approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we're focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.
About Provation
Provation is a leading provider of healthcare software and SaaS solutions, dedicated to empowering providers to deliver quality healthcare for all. Our comprehensive portfolio offers clinical productivity software that spans the entire patient encounter in the Anesthesia and GI (Gastroenterology) practices.
With a purpose-driven approach, Provation aims to streamline and enhance healthcare workflows for improved patient outcomes. Provation has a loyal customer base, serving more than 700 physician groups globally. In 2021, Provation was acquired by Fortive Corporation, a Fortune 1000 company that builds essential technology and accelerates transformation in high-impact fields like workplace safety, engineering, and healthcare. For more information about our solutions, visit provationmedical.com and follow us on Twitter, Facebook, and LinkedIn.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
21 minutes ago
- Business Wire
Wolters Kluwer Again Recognized as Clinical Decision Support Leader
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health has once again been identified as one of the top two companies in the new Frost Radar™ report on Clinical Decision Support Systems (CDSS). Evaluating over 60 companies, the Frost Radar spotlights 10; Wolters Kluwer was the only one named both a 'Company to Action' and the market leader for innovation. The company was also a leader in the 2023 report. Wolters Kluwer Health has been identified as one of the top two companies in the new Frost Radar™ report on Clinical Decision Support Systems (CDSS) and the only one named both a 'Company to Action' and the market leader for innovation. Share According to the Frost report, the top-right Radar position of Wolters Kluwer shows it 'has firmly established itself as a leader in the CDSS market, with impressive R&D investment, and recent and upcoming product launches. The company's strategic integration of emerging technologies, particularly Gen AI, has positioned it at the forefront of next-generation CDSS solutions.' The report also recognizes the company's redefinition of the CDSS category with its introduction of UpToDate Enterprise Edition stating it 'is designed to align buyers, administrators, and care teams on a singular platform. This strategic alignment is key in enhancing care delivery and realizing superior returns on investment. With advanced on-demand analytics, this edition offers system-level insights into product usage, community trends, education needs, and the overarching impact of UpToDate on healthcare systems.' 'The Frost Radar is a deep dive into the CDSS market and its vendors. Based on our analysis, Wolters Kluwer has achieved significant growth for its solutions by focusing on innovation and customer-centric solutions,' said Dr. Rishi Pathak, Global Director of Healthcare & Life Sciences, Frost & Sullivan. 'That, combined with their strategy to increase the reach of UpToDate through integration into the clinician workflow and the intention to address adjacent operational and financial workflows, puts them in the leadership position.' Wolters Kluwer Health recently announced the integration of UpToDate with several ambient AI leaders, including Abridge, Suki, Microsoft and others. 'Being named the innovation leader in the Frost Radar reinforces our focus on innovation and interconnectivity and validates our commitment to transforming healthcare through product innovation and strategic partnerships,' said Greg Samios, CEO of Wolters Kluwer Health. 'We remain dedicated to helping providers make faster, smarter decisions across the care continuum, while enabling organizations to maximize their UpToDate investment through insightful analytics, harmonized content, seamless integration, and AI-enhanced features.' Learn more about Wolters Kluwer in the Frost Radar on CDSS. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.


Business Wire
30 minutes ago
- Business Wire
Keysight and NIO Pioneer the Next Generation of Smart Electric Vehicles
SANTA ROSA, Calif.--(BUSINESS WIRE)-- Keysight Technologies, Inc. (NYSE: KEYS) has enabled NIO to successfully validate the wireless systems in its smart electric vehicles using Keysight network emulation solutions. As a result, NIO's vehicles now comply with 3GPP and IEEE 802.11 standards and deliver improved connectivity and performance to support the next generation of electric vehicle development. As vehicles become more connected to the world, there are several challenges to address, including ensuring compliance with evolving standards like 3GPP and IEEE 802.11 to guarantee reliable connectivity. Enhancing connectivity performance is crucial for features such as autonomous driving, real-time navigation, and in-car entertainment. To optimize the production and operational efficiency of smart vehicles, advanced automation, AI integration, and robust data interoperability are essential. Maintaining a competitive edge in this rapidly evolving market requires continuous innovation and adaptation to meet consumer and regulatory requirements. Keysight's network emulation solutions tackle this challenge by providing extensive testing for 3GPP and IEEE 802.11 for Wi-Fi 7, 4G, and 5G, as well as 5G New Radio (NR), Long-Term Evolution (LTE), vehicle-to-everything (V2X) and internet of things (IoT) radio frequency testing. The emulation capabilities enable NIO to meet the growing demands of smart mobility while still ensuring safety, compliance, and reliability. Key benefits include: High performance and improved reliability: by ensuring compliance with the latest 3GPP and IEEE standards, NIO's solutions achieve both performance and reliability helping to accelerate innovation. Improved time-to-market: with a streamlined and comprehensive testing process, NIO can identify any potential challenges earlier in the development process to increase speed to market. Optimized efficiency: with the rapid identification and resolution of RF performance issues, NIO can ensure agility in launching new solutions. Thomas Goetzl, Vice President and General Manager of Keysight's Automotive and Energy Solutions, said: 'Keysight's collaboration with NIO underscores the importance of rigorous testing and validation when it comes to delivering high-performing, future-ready vehicles. We are committed to driving technological innovation. This means working with our partners to ensure they have the tools and solutions needed to meet industry standards while also developing vehicles with safety, performance, and user experience at the heart.' Resources About Keysight Technologies At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we're delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product life cycle. We're a global innovation partner enabling customers in communications, industrial automation, aerospace and defense, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and
Yahoo
36 minutes ago
- Yahoo
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
BEIJING & NANJING, China, June 04, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTTQ") announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development. Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED. Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Contacts Biocytogen Contacts Antibody assets and platforms: BD-Licensing@ Media: pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data